Archives: Resources

June 5, 2019

Uncategorized

FDA appoints Public Private Partnership Liaison to ARC

To focus on the challenges faced by AL amyloidosis, a particularly complex and multi-systemic disease, and bridge the gaps in drug discovery and development . (more…)

May 6, 2019

Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) approved by FDA

This represents the first FDA approved treatment in ATTR-CM for both the wild-type and hereditary forms of ATTR amyloidosis. (more…)

May 1, 2019

Patient Perspectives from the FDA Public Meeting: the Impact of Rare Diseases

I recently had the opportunity to attend this public meeting at the FDA to discuss the Patient Perspectives on the Impact of Rare Diseases. This meeting was held as opportunity to bring the voices of patients and caregivers to the...

March 26, 2019

Advancing Amyloidosis: Roadmap for Research

FOR IMMEDIATE RELEASE LEADING EXPERTS PUBLISH A ROADMAP FOR CRITICAL AREAS OF RESEARCH IN AMYLOIDOSIS (more…)

March 12, 2019

ARC’s Advocates work Capitol Hill

Our ARC team of amyloidosis patients, caregivers and ARC staff took part as advocates in key activities during the week of Rare Disease Day, which is held on February 28th each year. (more…)

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
arc@arci.org